Metabolon, Inc., a Durham, NC-based diagnostics and services company offering a biochemical profiling technology, has secured $13.1m in a Series D financing.
New investor Keating Capital, Inc. has joined existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group (Nasdaq:TINY), Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners.
The company intends to use the funds to further grow its Metabolytics division and continue to develop its oncology diagnostics product portfolio.
Led by president and CEO John Ryals and CFO Todd Lynch, Metabolon offers a patented platform that provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease.
FinSMEs
29/08/2011